Published in Vaccine Weekly, March 8th, 2006
"Accumulation and aggregation of amyloid beta peptide 1-42 (A-beta(42)) in the brain has been hypothesized as triggering a pathological cascade that causes Alzheimer disease (AD). To determine whether selective targeting of A-beta42 versus A-beta40 or total A-beta is an effective way to prevent or treat AD, we compared the effects of passive immunization with an anti-A-beta42 mAb, an anti-A-beta40 MAb, and multiple A-beta1-16 mAbs," scientists in the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.